Cost-Effectiveness Analysis of Enfuvirtide (ENF) Added to an Optimized Therapy Compared with an Optimized Therapy in Patients with HIV/AIDS

REFERENCES

• Fauci AS. Twenty-five years of HIV/AIDS. Science. 2006;313:409.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006;8(4)191–203.
   Web of Science ®Google Scholar
• de Bethune MP, Hertogs K. Screening and selecting for op-timized antiretroviral drugs: rising to the challenge of drug resistance. Curr Med Res Opin. 2006;22(12):2603–2612.
   PubMed Web of Science ®Google Scholar
• Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust. 2007;186:146–151.
   Google Scholar
• Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497–1503.
   Google Scholar
• Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimi-crob Chemother 2006;58(2):235–242.
   PubMed Web of Science ®Google Scholar
• Clotet B. Strategies for overcoming resistance in HIV-1 in-fected patients receiving HAART. AIDS Rev. 2004;6(3):123–130.
   PubMed Web of Science ®Google Scholar
• Moatti JP, Spire B, Kazatchkine M. Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south. AIDS. 2004;18:S55–61.
   PubMedGoogle Scholar
• Sax PE. Updated DHHS treatment guidelines. AIDS Clin Care. 2006;18:105.
   PubMedGoogle Scholar
• Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3(5):371–378.
   PubMedGoogle Scholar
• Ruane P, Lang J, DeJesus E, et al. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. HIV Clin Tri-als. 2006;7(5):229–236.
   PubMed Web of Science ®Google Scholar
• Lzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348: 2175–2185.
   PubMed Web of Science ®Google Scholar
• Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses. 1999;15:499–508.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201–207.
   PubMed Web of Science ®Google Scholar
• Bycott P, Taylor J. A comparison of smoothing techniques for CD4 data measured with error in a time dependent Cox proportional hazards models. Stat Med. 1998;17:2061–2077.
   PubMed Web of Science ®Google Scholar
• Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymp-tomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991114: 798–802.
   Google Scholar
• Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 19914: 795–804.
   Google Scholar
• Simpson K, Hatziandreu EJ, Andersson F, Shakespeare A, Oleksy I, Tosteson AN. Cost effectiveness of antiviral treat-ment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries. Pharmacoeconomics. 1994;6:553–562.
   PubMed Web of Science ®Google Scholar
• Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection. An economic perspective. Pharmacoeco-nomics. 1996;10:109–113.
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Mar-kov model and trial data estimates. Am J Manag Care. 1998;4:1004–1012.
   PubMed Web of Science ®Google Scholar
• Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconom-ics. 1997;12:54–66.
   Google Scholar
• Caro JJ, O'Brien JA, Migliaccio-Walle K, Raggio G. Eco-nomic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. Pharmacoeconomics. 200119: 95–104.
   Google Scholar
• Hornberger J, Green J, Wintfeld N, et al. Cost-effective-ness of enfuvirtide for treatment experienced patients with HIV in Italy. HIV Clin Trials. 2005;6(2):92–102.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
   PubMed Web of Science ®Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuti-cos. PortalFarma.com. 2004. Available at: http://www.portalfarma.com
   Google Scholar
• Santin Cerezales M. Estimating the costs of health care for patients infected with the human immunodeficiency virus in a university hospital in Catalonia. Rev Clin Esp. 2004;198:429–432.
   Google Scholar
• Pinto JL, Lopez LC, Badia X, Coma A, Benavides A. [Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients]. Med Clin (Barc). 2000;114\(Suppl 3):62–67.
   PubMedGoogle Scholar
• Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001;134:440–450.
   PubMed Web of Science ®Google Scholar
• Biddle AK, Simpson N. Modelling the use of triple com-bination therapy in five countries: nevirapine, zidovudine, and didanosine. Value Health. 2000;3:186–201.
   PubMedGoogle Scholar
• Homberger J, Youle M, Beck EJ. Cost-effectiveness of en-fuvirtide from UK health perpspective. Paper presented at: Ninth European AIDS Conference, 2003; Warsaw, Poland.
   Google Scholar
• Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340(21):1683–1684.
   PubMed Web of Science ®Google Scholar
• Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Svndr. 2005;39:69–77.
   PubMed Web of Science ®Google Scholar
• Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. [What is an efficient health technology in Spain?]. Gac San/f. 2002;16:334–343.
   Google Scholar
• Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001;344:824–831.
   PubMed Web of Science ®Google Scholar